Latest Headlines

Latest Headlines

Cephalon scoops up cancer drugs in $525M Gemin X buyout

Intrigued by a lead program aimed at retriggering cell death in order to fight cancer, Cephalon ($CEPH) has gobbled up the small biotech Gemin X with a $225 million down payment and up to $300

Gemin X books $16M Series D as it pursues PhIIb cancer trial

Malvern, PA-based Gemin X Pharmaceuticals has rounded up $16 million in a Series D round led by two existing investors. The money will be put to use advancing the developer's new cancer therapies,